Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 AMPE | Healthcare | $0.18 | 0.00 | $207.88K | -0.02 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AMPE | Ampio Pharmaceuticals | 0.18 | 0.17 | 1730.00% |
| Name | Price | % Change | |
|---|---|---|---|
| AMPE | $0.18 | +1730.00% |
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics (CYTO), 15,822% surge in interest Stoke Therapeutics
Ampio announced that its board determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations
An announcement from Ampio Pharmaceuticals (AMPE) is now available. Ampio Pharmaceuticals, Inc. has announced the termination of its at-the-market equity distribution agreement with H.C. Wainwright & Co., LLC, effective March
Ampio Pharmaceuticals (AMPE) has released an update. Ampio Pharmaceuticals, Inc. has announced the successful completion of its recent nonclinical studies in a press release dated February 14, 2024. The company
Ampio announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio’s only product development opportunity. Ampio reported that the efficacy results of these studies do not
Ampio Pharmaceuticals (AMPE) has released an update. Ampio Pharmaceuticals, Inc. has engaged in an At The Market Offering Agreement with H. C. Wainwright & Co., LLC, allowing for the periodic
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Harpoon Therapeutics (HARP), 5,210% surge in interest Cellectar Biosciences
Ampio announced that its board of directors has approved a 20-to-1 reverse stock split of the company’s common stock. The reverse stock split will become effective on September 11. The
Ampio released the following letter to stockholders from its chairman, Kevin Buchi and CEO, Mike Martino. The company said, "On March 28, 2023, we filed our 2022 Annual Report on
Ampio Pharmaceuticals "announced that it has received notification from The NYSE American LLC stating that the Company has regained compliance with the NYSE American’s continued listing standards. Specifically, the Company
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
